Compare Amphastar Pharmaceuticals Inc (AMPH) vs SPDR Gold Trust (GLD) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

GLD trades at $376.91, down 0.34% on the day, with a bearish technical signal driven by moving averages. The stock lacks standard financial ratios (P/E, P/S, P/B, ROE) as it is an ETF tracking gold. Recent news highlights gold's 25% decline from highs, central bank buying support, and mixed sentiment ahead of CPI data and Federal Reserve policy cues, keeping prices range-bound near $4,100/oz equivalents.

Outlook hinges on macroeconomic factors: inflation data and Fed policy may test support levels, while geopolitical risks and central bank demand provide buffers. Risks include prolonged rate hikes pressuring gold, but long-term bullish fundamentals persist. Investors face volatility with no clear near-term catalyst for breakout.